FDA Accepts NDA Application for Troriluzole as Potential First Treatment for Spinocerebellar Ataxia
According to a new announcement from Biohaven, the FDA has accepted the company’s new drug application (NDA) for its investigational agent troriluzole, a third-generation prodrug that modulates glutamate, for the treatment of patients with spinocerebellar …